Skip to main content

Market Overview

Why Aerie Pharmaceuticals Is Trading Lower Today


Aerie Pharmaceuticals (NASDAQ: AERI) shares are trading lower on Monday after Bank of America downgraded the stock from Neutral to Underperform and announced a price target of $9 per share.

Aerie is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

Aerie Pharmaceuticals shares traded down 13.53% to $10.06 on Monday. The stock has a 52-week high of $26.26 and a 52-week low of $9.86.

Latest Ratings for AERI

Nov 2020HC Wainwright & Co.MaintainsBuy
Oct 2020B of A SecuritiesDowngradesNeutralUnderperform
Sep 2020GuggenheimInitiates Coverage OnBuy

View More Analyst Ratings for AERI
View the Latest Analyst Ratings


Related Articles (AERI)

View Comments and Join the Discussion!

Posted-In: why it's movingDowngrades Analyst Ratings

Latest Ratings

ICADGuggenheimInitiates Coverage On24.0
SMBKRaymond JamesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at